RT @gcfmd: @nl_pereira @JJheart_doc @JACCJournals PIONEER-HF enrolled 303 (34%) patients presenting with denovo HF and 576 (66%) with worse…
@nl_pereira @JJheart_doc @JACCJournals PIONEER-HF enrolled 303 (34%) patients presenting with denovo HF and 576 (66%) with worsening chronic HF There was no significant interaction between prior HF hx and the effect of S/V vs E on CV death/HF🏨 https://t.
@CianPMcCarthy @SABOURETCardio @JJheart_doc Agree - the PIONEER data support early initiation of ARNI in ACEI/ARB naïve patients as published by @KPHeartDoc @_adevore in @JACCJournals https://t.co/rf6M64mm7S
"Among patients admitted for acute decompensated HF, sacubitril-valsartan was safe and well tolerated, led to a significantly greater reduction in (NT-pro–BNP), and improved clinical outcomes" @ericjvelazquez @YaleCardiology https://t.co/zRIo3ARfL7
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists | JACC: Journal of the American College of Cardiology https://t.co/2wOhjjqtFe
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
In the PIONEER-HF study among patients admitted for acute decompensated HF, sacubitril/valsartan was safe and well tolerated and improved clinical outcomes compared with enalapril irrespective of previous HF history or ACE inhibitor or ARB treatment https:
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists https://t.co/AWT7dzhCLj
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @KPHeartDoc: New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment s…
RT @RxPDX: Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists | J…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists | JACC: Journal of the American College of Cardiology @KPHeartDoc #cardiotwitter https://t.co/6k3TJu7nsC
New data from PIONEER-HF suggest that ARNi therapy should be first-line irrespective of prior HF history or RAS treatment status. @ericjvelazquez @_adevore
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @JTLLERGO: Among patients admitted for Acute HF (PIONEER-HF): 📌 Sacubitril/Valsartan was safe and well tolerated 📌⬆️ reduction in NT-pro…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @JTLLERGO: Among patients admitted for Acute HF (PIONEER-HF): 📌 Sacubitril/Valsartan was safe and well tolerated 📌⬆️ reduction in NT-pro…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists | JACC: Journal of the American College of Cardiology @JACCJournals https://t.co/2OBcTMJHM0
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @JTLLERGO: Among patients admitted for Acute HF (PIONEER-HF): 📌 Sacubitril/Valsartan was safe and well tolerated 📌⬆️ reduction in NT-pro…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @gcfmd: Further support for ARNI first line Rx. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
RT @gcfmd: Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your…
Superior clinical outcomes with in-hospital initiation of ARNI vs. ACEI, for denovo HF or worsening chronic HF. Don’t let your HFrEF have fatal/non-fatal events due to delayed or never Rx. Take advantage of the teachable moment. #GDMTworks fast. @JJhe
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @gcfmd: Further support for ARNI first line Rx. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @gcfmd: Further support for ARNI first line Rx. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @gcfmd: Further support for ARNI first line Rx. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
ARNI usage is consistently proving superior to ACEi.
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
RT @JACCJournals: Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC res…
Compared to ACE-I, sacubitril-valsartan improves #heartfailure outcomes in acute decompensated HF, suggests new #JACC research: https://t.co/bag1k0ZghR https://t.co/0vtbhmXCCp
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…
RT @gcfmd: Further support for ARNI first line Rx. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of…
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists | JACC: Journal of the American College of Cardiology https://t.co/2wOhjjqtFe
RT @JTLLERGO: Among patients admitted for Acute HF (PIONEER-HF): 📌 Sacubitril/Valsartan was safe and well tolerated 📌⬆️ reduction in NT-pro…
RT @JTLLERGO: Among patients admitted for Acute HF (PIONEER-HF): 📌 Sacubitril/Valsartan was safe and well tolerated 📌⬆️ reduction in NT-pro…
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…
RT @gcfmd: Further support for ARNI first line Rx. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of…
RT @gcfmd: Further support for ARNI first line Rx. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of…
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…
I thought serially checking brain natriuretic protein was not useful in managing ADHF @MKIttlesonMD Change in NTproBNP concentration is a very "soft" maybe worthless outcome CV death and HF rehospitalizations (secondary outcomes) are far more relevant
24% additional reduction in ntPro BNP in patients already on ACEI/ARB when ARNI is given
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…
RT @JTLLERGO: Among patients admitted for Acute HF (PIONEER-HF): 📌 Sacubitril/Valsartan was safe and well tolerated 📌⬆️ reduction in NT-pro…
メモ。Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists | JACC: Journal of the American College of Cardiology https://t.co/gE4VNCGV6B
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…
RT @JonathanDavisHF: Further evidence that ARNI is 1st line for RAAS inhibition for #GDMTWorks for #HFrEF. #QuadTherapy: BB + ARNI + MRA +…